Peripheral neuropathy
Nerve damage in the peripheral nervous system — diabetic, chemotherapy-induced, idiopathic small-fiber, alcoholic, or post-infectious — covering what standard-of-care looks like and where peptide-adjacent molecules genuinely have a clinical case versus where the case is community framing without evidence.
What changes during this transition
Peripheral neuropathy is a broad category covering distinct underlying drivers — diabetic peripheral neuropathy (DPN, affecting roughly half of T2D patients lifetime), chemotherapy-induced peripheral neuropathy (CIPN, the dose-limiting toxicity of taxanes, platinums, vincas, and bortezomib), idiopathic small-fiber neuropathy, alcoholic neuropathy, and post-infectious neuropathy including post-COVID and Guillain-Barré sequelae. The standard-of-care framework in the US is well-defined: AAN 2011 + ADA 2017 + ASCO 2014 guidelines anchor the pharmacological pathway (pregabalin and duloxetine FDA-approved for DPN; duloxetine the only positive-trial intervention for CIPN per Smith 2013 JAMA; gabapentin, TCAs like amitriptyline/nortriptyline off-label; topical capsaicin 8% patch and lidocaine 5% patch for focal symptoms; opioids last-line). Glycemic control is the only intervention that modifies underlying disease course in diabetic neuropathy per the ADA position statement; alcohol cessation is the equivalent for alcoholic neuropathy; B12 repletion treats confirmed deficiency. The library's strongest peptide-adjacent case here is B12-methylcobalamin, and the editorial register shifts meaningfully — methylcobalamin 500 mcg three-times-daily is the registered or routinely-prescribed standard for diabetic and idiopathic peripheral neuropathy across Japan, China, India, South Korea, Taiwan, the Philippines, and Thailand. This is labeled use globally, not extrapolation; the US AAN 2011 framing of 'not first-line for non-deficient DPN' is the outlier internationally. The metformin-induced B12 deficiency angle (Pflipsen 2009, Singh 2013 — roughly 30% prevalence after 3+ years) is particularly load-bearing because metformin users are the same population most likely to have DPN. Cerebrolysin and semax surface as registered neurotrophic options in their source jurisdictions (cerebrolysin in 50+ countries for stroke/dementia/TBI; semax with Russian MoH 1994 cerebrovascular registration), both with peripheral-neuropathy-specific trial work that's thinner than their headline indications and capped at Tier 3 by cross-jurisdictional replication gaps. BPC-157 and thymosin α-1 are NOT surfaced as discovery options: BPC-157 has rodent sciatic-nerve-crush mechanism data but zero human peripheral neuropathy trial; thymosin α-1's immune-modulation mechanism isn't aligned with CIPN's actual pathophysiology (mitochondrial + oxidative + neuroinflammatory direct neurotoxicity) and there's no peripheral neuropathy trial in any etiology. Substrate exists on both for honest /ask answers.
Important caveat
Standard-of-care comes first and runs through neurology — peripheral neuropathy workup matters because the underlying driver determines the intervention. For diabetic neuropathy: glycemic control (A1C, time-in-range) is the only disease-modifying intervention per the ADA position statement; pregabalin (Lyrica, FDA-approved) and duloxetine (Cymbalta, FDA-approved for DPN and CIPN) are the AAN-guideline first-line pharmacological options; gabapentin, amitriptyline, and nortriptyline are off-label alternatives; topical capsaicin 8% patch (Qutenza, FDA-approved) and lidocaine 5% patch handle focal symptoms; tramadol and tapentadol sit higher in the pain ladder; opioids are last-line. For CIPN: dose-modification with the treating oncology team is the foundation, duloxetine is the only positive-trial intervention (Smith 2013 JAMA, ASCO 2014 guidelines), and any peptide consideration sits downstream of those. For alcoholic neuropathy: alcohol cessation is the foundation. B12 deficiency workup — serum B12 plus methylmalonic acid plus homocysteine — should be standard before assuming B12 isn't the driver, because serum-only screening misses functional deficiency, and metformin users should get this annually after year 2. Small-fiber neuropathy needs a specific workup pathway including skin biopsy with epidermal nerve fiber density and autoimmune/metabolic/genetic etiology screening; missing that workup means missing treatable causes regardless of what's added on top. The multi-jurisdictional clinical evidence for methylcobalamin in DPN and idiopathic neuropathy is real and shouldn't be dismissed as 'no US trials' — but it sits alongside, not instead of, the US standard-of-care framework, and any decision belongs with the treating neurologist or primary care clinician managing the underlying driver.
Peptides editorially relevant to peripheral neuropathy
3 peptides from the library — each evidence-tiered honestly.
- B12 (Methylcobalamin)Tier 1
Vitamin (methylcobalamin)
Vitamin B12 in the methyl form. Solid evidence for treating documented deficiency and pernicious anemia. The wellness-clinic 'energy injection' market for non-deficient adults has no clinical-trial support.
- CerebrolysinTier 2
Porcine-derived neuropeptide mixture
Multi-peptide cocktail from porcine brain, manufactured by EVER Pharma. Approved in Europe / Asia / Russia for ischemic stroke, dementia, and TBI. NOT US-approved. Tier 1/2 abroad in approved indications; Tier 3 for off-label use.
- SemaxTier 3
Synthetic ACTH(4-10) analog (heptapeptide)
Russian-developed nootropic and neuroprotective peptide. Registered there as a prescription product for stroke; most of the clinical evidence is Russian-language and not independently replicated outside that body of work.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.